Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis

Company Overview

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Key Stats

• Today's Range: $6.65 to $6.79
• 50-Day Range: $4.74 to $7.18
• 52-Week Range: $2.12 to $12.55
• Volume: 8,695 shs
• Average Volume: 31,229 shs
• Market Capitalization: $12.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

NEUP Stock Analysis - Frequently Asked Questions

How have NEUP shares performed this year?

Neuphoria Therapeutics' stock was trading at $3.20 at the start of the year. Since then, NEUP stock has increased by 111.3% and is now trading at $6.76.
View the best growth stocks for 2025 here.

How were Neuphoria Therapeutics' earnings last quarter?

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) issued its quarterly earnings data on Tuesday, May, 20th. The company reported $6.55 earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $7.02. The business had revenue of $15 million for the quarter.

Who are Neuphoria Therapeutics' major shareholders?

Top institutional investors of Neuphoria Therapeutics include Cyndeo Wealth Partners LLC (0.57%).

How do I buy shares of Neuphoria Therapeutics?

Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/20/2025
• Today: 6/18/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NEUP
• Previous Symbol: NASDAQ:NEUP
• CIK: 1191070
• Web: www.bionomics.com.au
• Phone: 61-8-8150-7400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +210.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.01
• Quick Ratio: 11.01

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,270.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.85 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 1,880,000
• Free Float: 1,867,000
• Market Cap: $12.71 million
• Optionable: N/A
• Beta: 0.46